{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T01:19:47Z","timestamp":1793841587323,"version":"4.6.1"},"reference-count":100,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100002608","name":"American Thyroid Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002608","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["DK067555"],"award-info":[{"award-number":["DK067555"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["DK073681"],"award-info":[{"award-number":["DK073681"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000901","name":"Juvenile Diabetes Research Foundation International","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000901","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.beem.2022.101661","type":"journal-article","created":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T11:30:19Z","timestamp":1649676619000},"page":"101661","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":65,"title":["Genetics and epigenetics of autoimmune thyroid diseases: Translational implications"],"prefix":"10.1016","volume":"37","author":[{"given":"Hanna J.","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihaela","family":"Stefan\u2013Lifshitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheuk Wun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaron","family":"Tomer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.beem.2022.101661_bib1","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1210\/jcem.87.2.8182","article-title":"Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): national health and nutrition examination survey (NHANES III)","volume":"87","author":"Hollowell","year":"2002","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2022.101661_bib2","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jaut.2007.02.006","article-title":"The CD40, CTLA-4, thyroglobulin, TSH receptor, and PTPN22 gene quintet and its contribution to thyroid autoimmunity: back to the future","volume":"28","author":"Jacobson","year":"2007","journal-title":"J\u00a0Autoimmun"},{"key":"10.1016\/j.beem.2022.101661_bib3","doi-asserted-by":"crossref","first-page":"15119","DOI":"10.1073\/pnas.2434175100","article-title":"Amino acid substitutions in the thyroglobulin gene are associated with susceptibility to human and murine autoimmune thyroid disease","volume":"100","author":"Ban","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.beem.2022.101661_bib4","doi-asserted-by":"crossref","first-page":"111227","DOI":"10.1016\/j.mce.2021.111227","article-title":"Structure and genetic variants of thyroglobulin: pathophysiological implications","volume":"528","author":"Citterio","year":"2021","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.beem.2022.101661_bib5","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/s41572-020-0184-y","article-title":"Graves' disease","volume":"6","author":"Davies","year":"2020","journal-title":"Nat Rev Dis Prim"},{"key":"10.1016\/j.beem.2022.101661_bib6","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.3389\/fimmu.2017.01845","article-title":"Thyroid autoantibodies display both \"original antigenic sin\" and epitope spreading","volume":"8","author":"McLachlan","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.beem.2022.101661_bib7","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1055\/s-0035-1559633","article-title":"Graves' disease mechanisms: the role of stimulating, blocking, and cleavage region TSH receptor antibodies","volume":"47","author":"Morshed","year":"2015","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.beem.2022.101661_bib8","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1007\/s12026-012-8302-x","article-title":"Genetic and epigenetic mechanisms in thyroid autoimmunity","volume":"54","author":"Hasham","year":"2012","journal-title":"Immunol Res"},{"key":"10.1016\/j.beem.2022.101661_bib9","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1089\/thy.2010.1638","article-title":"The genetics of the thyroid stimulating hormone receptor: history and relevance","volume":"20","author":"Davies","year":"2010","journal-title":"Thyroid"},{"key":"10.1016\/j.beem.2022.101661_bib10","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3389\/fendo.2017.00057","article-title":"Genetics of thyroid-stimulating hormone receptor-relevance for autoimmune thyroid disease","volume":"8","author":"Stefan","year":"2017","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.beem.2022.101661_bib11","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jaut.2009.02.007","article-title":"The etiology of autoimmune thyroid disease: a story of genes and environment","volume":"32","author":"Tomer","year":"2009","journal-title":"J\u00a0Autoimmun"},{"key":"10.1016\/j.beem.2022.101661_bib12","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1093\/hmg\/ddp087","article-title":"Association of the thyroid stimulating hormone receptor gene (TSHR) with Graves' disease","volume":"18","author":"Brand","year":"2009","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.beem.2022.101661_bib13","doi-asserted-by":"crossref","first-page":"31168","DOI":"10.1074\/jbc.M111.247510","article-title":"Novel variant of thyroglobulin promoter triggers thyroid autoimmunity through an epigenetic interferon alpha-modulated mechanism","volume":"286","author":"Stefan","year":"2011","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.beem.2022.101661_bib14","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.2147\/OPTH.S136070","article-title":"Single nucleotide polymorphism 1623 A\/G (rs180195) in the promoter of the Thyroglobulin gene is associated with autoimmune thyroid disease but not with thyroid ophthalmopathy","volume":"11","author":"Lahooti","year":"2017","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.beem.2022.101661_bib15","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/BF03346699","article-title":"Environmental triggers of thyroiditis: hepatitis C and interferon-alpha","volume":"34","author":"Menconi","year":"2011","journal-title":"J\u00a0Endocrinol Invest"},{"key":"10.1016\/j.beem.2022.101661_bib16","doi-asserted-by":"crossref","first-page":"J322","DOI":"10.1016\/j.jaut.2009.11.008","article-title":"Hepatitis C and interferon induced thyroiditis","volume":"34","author":"Tomer","year":"2010","journal-title":"J\u00a0Autoimmun"},{"key":"10.1016\/j.beem.2022.101661_bib17","doi-asserted-by":"crossref","first-page":"3678","DOI":"10.1210\/jc.2018-00541","article-title":"Interferon-alpha triggers autoimmune thyroid diseases via lysosomal-dependent degradation of thyroglobulin","volume":"103","author":"Faustino","year":"2018","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2022.101661_bib18","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1080\/10409238.2019.1610351","article-title":"Proteasomal and lysosomal clearance of faulty secretory proteins: ER-associated degradation (ERAD) and ER-to-lysosome-associated degradation (ERLAD) pathways","volume":"54","author":"Fregno","year":"2019","journal-title":"Crit Rev Biochem Mol Biol"},{"key":"10.1016\/j.beem.2022.101661_bib19","doi-asserted-by":"crossref","first-page":"34231","DOI":"10.1074\/jbc.M109.041574","article-title":"Employing a recombinant HLA-DR3 expression system to dissect major histocompatibility complex II-thyroglobulin peptide dynamism: a genetic, biochemical, and reverse immunological perspective","volume":"284","author":"Jacobson","year":"2009","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.beem.2022.101661_bib20","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1074\/jbc.M115.694687","article-title":"Identifying a small molecule blocking antigen presentation in autoimmune thyroiditis","volume":"291","author":"Li","year":"2016","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.beem.2022.101661_bib21","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jaut.2010.01.004","article-title":"Tg.2098 is a major human thyroglobulin T-cell epitope","volume":"35","author":"Menconi","year":"2010","journal-title":"J\u00a0Autoimmun"},{"key":"10.1016\/j.beem.2022.101661_bib22","doi-asserted-by":"crossref","first-page":"795","DOI":"10.4049\/jimmunol.181.1.795","article-title":"Thyroglobulin peptides associate in\u00a0vivo to HLA-DR in autoimmune thyroid glands","volume":"181","author":"Muixi","year":"2008","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.beem.2022.101661_bib23","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.cellimm.2004.07.002","article-title":"Pathogenic human thyroglobulin peptides in HLA-DR3 transgenic mouse model of autoimmune thyroiditis","volume":"229","author":"Flynn","year":"2004","journal-title":"Cell Immunol"},{"key":"10.1016\/j.beem.2022.101661_bib24","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1080\/08916934.2017.1344971","article-title":"Association of the polymorphisms in the gene encoding thyroglobulin with the development and prognosis of autoimmune thyroid disease","volume":"50","author":"Mizuma","year":"2017","journal-title":"Autoimmunity"},{"issue":"9","key":"10.1016\/j.beem.2022.101661_bib25","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1089\/thy.2019.0711","article-title":"A\u00a0novel mouse model of autoimmune thyroiditis induced by immunization with adenovirus containing full-length thyroglobulin cDNA: implications to genetic studies of thyroid autoimmunity","volume":"30","author":"Faustino","year":"2020","journal-title":"Thyroid"},{"key":"10.1016\/j.beem.2022.101661_bib26","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.3389\/fimmu.2019.01695","article-title":"Regulation of TSHR expression in the thyroid and thymus may contribute to TSHR tolerance failure in graves' disease patients via two distinct mechanisms","volume":"10","author":"Marin-Sanchez","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.beem.2022.101661_bib27","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1093\/hmg\/ddr247","article-title":"Association of an SNP with intrathymic transcription of TSHR and Graves' disease: a role for defective thymic tolerance","volume":"20","author":"Colobran","year":"2011","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.beem.2022.101661_bib28","doi-asserted-by":"crossref","first-page":"12562","DOI":"10.1073\/pnas.1408821111","article-title":"Genetic-epigenetic dysregulation of thymic TSH receptor gene expression triggers thyroid autoimmunity","volume":"111","author":"Stefan","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.beem.2022.101661_bib29","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1126\/science.1246755","article-title":"Genetics. Genetics driving epigenetics","volume":"342","author":"Furey","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.beem.2022.101661_bib30","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41588-017-0015-6","article-title":"Identification of H3K4me1-associated proteins at mammalian enhancers","volume":"50","author":"Local","year":"2018","journal-title":"Nat Genet"},{"key":"10.1016\/j.beem.2022.101661_bib31","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jaut.2018.08.003","article-title":"Interferon alpha: the key trigger of type 1 diabetes","volume":"94","author":"Lombardi","year":"2018","journal-title":"J\u00a0Autoimmun"},{"key":"10.1016\/j.beem.2022.101661_bib32","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1912196","article-title":"Trial of anifrolumab in active systemic lupus erythematosus","volume":"382","author":"Morand","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2022.101661_bib33","first-page":"658","article-title":"FDA approves AstraZeneca's anifrolumab for lupus","volume":"20","author":"Mullard","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.beem.2022.101661_bib34","first-page":"1662","article-title":"Type I interferon-mediated autoimmune diseases: pathogenesis, diagnosis and targeted therapy","volume":"56","author":"Psarras","year":"2017","journal-title":"Rheumatology"},{"key":"10.1016\/j.beem.2022.101661_bib35","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jaut.2007.11.010","article-title":"The HLA gene complex in thyroid autoimmunity: from epidemiology to etiology","volume":"30","author":"Jacobson","year":"2008","journal-title":"J\u00a0Autoimmun"},{"key":"10.1016\/j.beem.2022.101661_bib36","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/sj.gene.6364059","article-title":"Arginine at position 74 of the HLA-DR beta 1 chain is associated with Graves' disease","volume":"5","author":"Ban","year":"2004","journal-title":"Gene Immun"},{"key":"10.1016\/j.beem.2022.101661_bib37","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1365-2265.1980.tb03421.x","article-title":"Graves' disease and HLA: clinical and epidemiologic associations","volume":"13","author":"Farid","year":"1980","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.beem.2022.101661_bib38","doi-asserted-by":"crossref","first-page":"14034","DOI":"10.1073\/pnas.0806584105","article-title":"Molecular amino acid signatures in the MHC class II peptide-binding pocket predispose to autoimmune thyroiditis in humans and in mice","volume":"105","author":"Menconi","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.beem.2022.101661_bib39","doi-asserted-by":"crossref","first-page":"16899","DOI":"10.1073\/pnas.1009511107","article-title":"Shared molecular amino acid signature in the HLA-DR peptide binding pocket predisposes to both autoimmune diabetes and thyroiditis","volume":"107","author":"Menconi","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.beem.2022.101661_bib40","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1056\/NEJMra030158","article-title":"Autoimmune polyendocrine syndromes","volume":"350","author":"Eisenbarth","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2022.101661_bib41","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1210\/er.2008-0015","article-title":"Joint genetic susceptibility to type 1 diabetes and autoimmune thyroiditis: from epidemiology to mechanisms","volume":"29","author":"Huber","year":"2008","journal-title":"Endocr Rev"},{"key":"10.1016\/j.beem.2022.101661_bib42","doi-asserted-by":"crossref","first-page":"5074","DOI":"10.4049\/jimmunol.1300407","article-title":"Small molecule inhibitor of antigen binding and presentation by HLA-DR2b as a therapeutic strategy for the treatment of multiple sclerosis","volume":"191","author":"Ji","year":"2013","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.beem.2022.101661_bib43","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1172\/JCI97739","article-title":"Methyldopa blocks MHC class II binding to disease-specific antigens in autoimmune diabetes","volume":"128","author":"Ostrov","year":"2018","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.beem.2022.101661_bib44","doi-asserted-by":"crossref","first-page":"102402","DOI":"10.1016\/j.jaut.2020.102402","article-title":"Cepharanthine blocks TSH receptor peptide presentation by HLA-DR3: therapeutic implications to Graves' disease","volume":"108","author":"Li","year":"2020","journal-title":"J\u00a0Autoimmun"},{"key":"10.1016\/j.beem.2022.101661_bib45","doi-asserted-by":"crossref","first-page":"796552","DOI":"10.3389\/fimmu.2021.796552","article-title":"Cepharanthine blocks presentation of thyroid and islet peptides in a novel humanized autoimmune diabetes and thyroiditis mouse model","volume":"12","author":"Li","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.beem.2022.101661_bib46","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0065-2776(08)60284-9","article-title":"Thyroid antigens and autoimmunity","volume":"14","author":"Shulman","year":"1971","journal-title":"Adv Immunol"},{"key":"10.1016\/j.beem.2022.101661_bib47","doi-asserted-by":"crossref","first-page":"4583","DOI":"10.1210\/en.2010-0321","article-title":"Antibodies to thyroid peroxidase arise spontaneously with age in NOD.H-2h4 mice and appear after thyroglobulin antibodies","volume":"151","author":"Chen","year":"2010","journal-title":"Endocrinology"},{"key":"10.1016\/j.beem.2022.101661_bib48","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1210\/jc.2005-2537","article-title":"Thyrotropin receptor epitopes and their relation to histocompatibility leukocyte antigen-DR molecules in Graves' disease","volume":"91","author":"Inaba","year":"2006","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2022.101661_bib49","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.4049\/jimmunol.168.6.2789","article-title":"A\u00a0novel murine model of Graves' hyperthyroidism with intramuscular injection of adenovirus expressing the thyrotropin receptor","volume":"168","author":"Nagayama","year":"2002","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.beem.2022.101661_bib50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2016.09.007","article-title":"Flexible peptide recognition by HLA-DR triggers specific autoimmune T-cell responses in autoimmune thyroiditis and diabetes","volume":"76","author":"Li","year":"2017","journal-title":"J\u00a0Autoimmun"},{"key":"10.1016\/j.beem.2022.101661_bib51","doi-asserted-by":"crossref","first-page":"152956","DOI":"10.1016\/j.phymed.2019.152956","article-title":"Cepharanthine: an update of its mode of action, pharmacological properties and medical applications","volume":"62","author":"Bailly","year":"2019","journal-title":"Phytomedicine : international journal of phytotherapy and phytopharmacology"},{"key":"10.1016\/j.beem.2022.101661_bib52","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.intimp.2012.04.015","article-title":"Low dose cepharanthine ameliorates immune thrombocytopenic purpura associated with multiple myeloma","volume":"13","author":"Tabata","year":"2012","journal-title":"Int Immunopharm"},{"key":"10.1016\/j.beem.2022.101661_bib53","first-page":"471","article-title":"[Effect of cepharanthin on radiotherapy induced leukopenia]","volume":"35","author":"Ohta","year":"1990","journal-title":"Rinsho hoshasen Clinical radiography"},{"key":"10.1016\/j.beem.2022.101661_bib54","first-page":"647","article-title":"[Effects of cepharanthin on leukopenia and thrombocytopenia induced by chemotherapy in lung cancer patients]","volume":"19","author":"Suzuki","year":"1992","journal-title":"Gan to kagaku ryoho Cancer & chemotherapy"},{"key":"10.1016\/j.beem.2022.101661_bib55","first-page":"71","article-title":"Therapeutic experience of venomous snakebites by the Japanese viper (Agkistrodon halys Blomhoffii) with low dose of antivenin: report of 43 consecutive cases","volume":"66","author":"Kimoto","year":"1997","journal-title":"Nihon Geka Hokan"},{"key":"10.1016\/j.beem.2022.101661_bib56","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.3892\/ijo_00000417","article-title":"Cepharanthine inhibits angiogenesis and tumorigenicity of human oral squamous cell carcinoma cells by suppressing expression of vascular endothelial growth factor and interleukin-8","volume":"35","author":"Harada","year":"2009","journal-title":"Int J Oncol"},{"key":"10.1016\/j.beem.2022.101661_bib57","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1254\/fpj.90.205","article-title":"[Mode of the anti-allergic action of cepharanthine on an experimental model of allergic rhinitis]","volume":"90","author":"Kohno","year":"1987","journal-title":"Nihon Yakurigaku Zasshi"},{"key":"10.1016\/j.beem.2022.101661_bib58","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1254\/jjp.54.464","article-title":"Reversal of resistance to doxorubicin with cepharanthine in murine P388 leukemia cells","volume":"54","author":"Fujimura","year":"1990","journal-title":"Jpn J Pharmacol"},{"key":"10.1016\/j.beem.2022.101661_bib59","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2174\/138920207783591690","article-title":"The HLA region and autoimmune disease: associations and mechanisms of action","volume":"8","author":"Gough","year":"2007","journal-title":"Curr Genom"},{"key":"10.1016\/j.beem.2022.101661_bib60","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1146\/annurev-pathol-012513-104713","article-title":"Mechanisms of autoimmune thyroid diseases: from genetics to epigenetics","volume":"9","author":"Tomer","year":"2014","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.beem.2022.101661_bib61","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1089\/105072502321085234","article-title":"A\u00a0C\/T single-nucleotide polymorphism in the region of the CD40 gene is associated with Graves' disease","volume":"12","author":"Tomer","year":"2002","journal-title":"Thyroid"},{"key":"10.1016\/j.beem.2022.101661_bib62","article-title":"Genetic study in a large cohort supported different pathogenesis of graves' disease and hashimoto's hypothyroidism","volume":"105","author":"Zhang","year":"2020","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2022.101661_bib63","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.smim.2009.05.012","article-title":"CD40 and autoimmunity: the dark side of a great activator","volume":"21","author":"Peters","year":"2009","journal-title":"Semin Immunol"},{"key":"10.1016\/j.beem.2022.101661_bib64","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.addr.2018.12.005","article-title":"Targeting the CD40-CD40L pathway in autoimmune diseases: humoral immunity and beyond","volume":"141","author":"Karnell","year":"2019","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.beem.2022.101661_bib65","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1146\/annurev.immunol.16.1.111","article-title":"CD40 and CD154 in cell-mediated immunity","volume":"16","author":"Grewal","year":"1998","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.beem.2022.101661_bib66","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/nri1462","article-title":"The multifaceted roles of TRAFs in the regulation of B-cell function","volume":"4","author":"Bishop","year":"2004","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.beem.2022.101661_bib67","doi-asserted-by":"crossref","first-page":"197","DOI":"10.4274\/jcrpe.galenos.2019.2019.0108","article-title":"Soluble CD40 ligand levels in children with newly diagnosed graves' disease","volume":"12","author":"Metwalley","year":"2020","journal-title":"J\u00a0Clin Res Pediatr Endocrinol"},{"key":"10.1016\/j.beem.2022.101661_bib68","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.clim.2018.11.007","article-title":"The hyper IgM syndromes: epidemiology, pathogenesis, clinical manifestations, diagnosis and management","volume":"198","author":"Yazdani","year":"2019","journal-title":"Clin Immunol"},{"key":"10.1016\/j.beem.2022.101661_bib69","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1210\/en.2004-1617","article-title":"A\u00a0Graves' disease-associated Kozak sequence single-nucleotide polymorphism enhances the efficiency of CD40 gene translation: a case for translational pathophysiology","volume":"146","author":"Jacobson","year":"2005","journal-title":"Endocrinology"},{"key":"10.1016\/j.beem.2022.101661_bib70","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1089\/thy.2005.15.1119","article-title":"Association of CD40 gene polymorphism (C-1T) with susceptibility and phenotype of Graves' disease","volume":"15","author":"Kurylowicz","year":"2005","journal-title":"Thyroid"},{"key":"10.1016\/j.beem.2022.101661_bib71","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1089\/thy.2006.16.443","article-title":"Association of a C\/T single-nucleotide polymorphism in the 5' untranslated region of the CD40 gene with Graves' disease in Japanese","volume":"16","author":"Ban","year":"2006","journal-title":"Thyroid"},{"key":"10.1016\/j.beem.2022.101661_bib72","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1089\/105072503322511319","article-title":"A\u00a0C\/T polymorphism in the 5'-untranslated region of the CD40 gene is associated with Graves' disease in Koreans","volume":"13","author":"Kim","year":"2003","journal-title":"Thyroid"},{"key":"10.1016\/j.beem.2022.101661_bib73","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1530\/EJE-08-0410","article-title":"Association of CD40 and thyroglobulin genes with later-onset Graves' disease in Taiwanese patients","volume":"159","author":"Hsiao","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2022.101661_bib74","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1159\/000342621","article-title":"Genotype and phenotype predictors of relapse of graves' disease after antithyroid drug withdrawal","volume":"1","author":"Wang","year":"2013","journal-title":"Eur Thyroid J"},{"key":"10.1016\/j.beem.2022.101661_bib75","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s00296-014-3171-3","article-title":"Associations of rs4810485 and rs1883832 polymorphisms of CD40 gene with susceptibility and clinical findings of Behcet's disease","volume":"35","author":"Inal","year":"2015","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.beem.2022.101661_bib76","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.3899\/jrheum.100362","article-title":"Influence of CD40 rs1883832 polymorphism in susceptibility to and clinical manifestations of biopsy-proven giant cell arteritis","volume":"37","author":"Rodriguez-Rodriguez","year":"2010","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.beem.2022.101661_bib77","doi-asserted-by":"crossref","first-page":"642929","DOI":"10.3389\/fimmu.2021.642929","article-title":"Association of CD40 gene polymorphisms with systemic lupus erythematosus and rheumatoid arthritis in a Chinese han population","volume":"12","author":"Huang","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.beem.2022.101661_bib78","doi-asserted-by":"crossref","first-page":"144419","DOI":"10.1016\/j.gene.2020.144419","article-title":"Impact of CD40 gene polymorphisms on the risk of immune thrombocytopenic purpura","volume":"736","author":"AbdelGhafar","year":"2020","journal-title":"Gene"},{"key":"10.1016\/j.beem.2022.101661_bib79","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.humimm.2011.05.014","article-title":"A\u00a0CD40 and an NCOA5 gene polymorphism confer susceptibility to psoriasis in a Southern European population: a case-control study","volume":"72","author":"Zervou","year":"2011","journal-title":"Hum Immunol"},{"key":"10.1016\/j.beem.2022.101661_bib80","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1038\/ng.233","article-title":"Common variants at CD40 and other loci confer risk of rheumatoid arthritis","volume":"40","author":"Raychaudhuri","year":"2008","journal-title":"Nat Genet"},{"key":"10.1016\/j.beem.2022.101661_bib81","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/08916930400002386","article-title":"The role of CD40-CD154 interactions in autoimmunity and the benefit of disrupting this pathway","volume":"37","author":"Toubi","year":"2004","journal-title":"Autoimmunity"},{"key":"10.1016\/j.beem.2022.101661_bib82","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1093\/cvr\/cvz206","article-title":"Functional association of a CD40 gene single-nucleotide polymorphism with the pathogenesis of coronary heart disease","volume":"116","author":"Sultan","year":"2020","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.beem.2022.101661_bib83","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1164\/rccm.200609-1286OC","article-title":"Association analysis of CD40 polymorphisms with asthma and the level of serum total IgE","volume":"175","author":"Park","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.beem.2022.101661_bib84","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1006\/clin.1997.4391","article-title":"Coexpression of CD40 and class II antigen HLA-DR in Graves' disease thyroid epithelial cells","volume":"84","author":"Faure","year":"1997","journal-title":"Clin Immunol Immunopathol"},{"key":"10.1016\/j.beem.2022.101661_bib85","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1089\/thy.1999.9.749","article-title":"CD40 expression in human thyroid tissue: evidence for involvement of multiple cell types in autoimmune and neoplastic diseases","volume":"9","author":"Smith","year":"1999","journal-title":"Thyroid"},{"key":"10.1016\/j.beem.2022.101661_bib86","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1167\/iovs.08-2328","article-title":"Orbital fibroblasts from patients with thyroid-associated ophthalmopathy overexpress CD40: CD154 hyperinduces IL-6, IL-8, and MCP-1","volume":"50","author":"Hwang","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.beem.2022.101661_bib87","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.4049\/jimmunol.1200311","article-title":"Genetically driven target tissue overexpression of CD40: a novel mechanism in autoimmune disease","volume":"189","author":"Huber","year":"2012","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.beem.2022.101661_bib88","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1210\/en.2016-1609","article-title":"CD40 signaling in graves disease is mediated through canonical and noncanonical thyroidal nuclear factor kappaB activation","volume":"158","author":"Lee","year":"2017","journal-title":"Endocrinology"},{"key":"10.1016\/j.beem.2022.101661_bib89","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1089\/thy.2006.16.427","article-title":"Blockade of costimulation between T cells and antigen-presenting cells: an approach to suppress murine Graves' disease induced using thyrotropin receptor-expressing adenovirus","volume":"16","author":"Chen","year":"2006","journal-title":"Thyroid"},{"key":"10.1016\/j.beem.2022.101661_bib90","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1089\/thy.1996.6.267","article-title":"Antibody to gp39, the ligand for CD40 significantly inhibits the humoral response from Graves' thyroid tissues xenografted into severe combined immunodeficient (SCID) mice","volume":"6","author":"Resetkova","year":"1996","journal-title":"Thyroid"},{"key":"10.1016\/j.beem.2022.101661_bib91","article-title":"Targeting the CD40-cd154 signaling pathway for treatment of autoimmune","volume":"8","author":"Lai","year":"2019","journal-title":"Arthritis. Cells"},{"key":"10.1016\/j.beem.2022.101661_bib92","first-page":"1506","article-title":"Increased CD40 expression on articular chondrocytes from patients with rheumatoid arthritis: contribution to production of cytokines and matrix metalloproteinases","volume":"31","author":"Gotoh","year":"2004","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.beem.2022.101661_bib93","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1080\/03009742.2018.1432684","article-title":"Increased expression of CD40\/TRAF1 and activation of nuclear factor-kappakappaB-dependent proinflammatory gene expression in collagen-induced arthritis","volume":"47","author":"Cheng","year":"2018","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.beem.2022.101661_bib94","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.4049\/jimmunol.176.4.2617","article-title":"TNF-alpha blockade down-regulates the CD40\/CD40L pathway in the mucosal microcirculation: a novel anti-inflammatory mechanism of infliximab in Crohn's disease","volume":"176","author":"Danese","year":"2006","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.beem.2022.101661_bib95","doi-asserted-by":"crossref","first-page":"102668","DOI":"10.1016\/j.autrev.2020.102668","article-title":"Phoenix from the flames: rediscovering the role of the CD40-CD40L pathway in systemic lupus erythematosus and lupus nephritis","volume":"19","author":"Ramanujam","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.beem.2022.101661_bib96","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.atherosclerosis.2004.05.008","article-title":"Increased CD40 ligand and platelet-monocyte aggregates in patients with type 1 diabetes mellitus","volume":"176","author":"Harding","year":"2004","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.beem.2022.101661_bib97","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/72162","article-title":"Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand","volume":"6","author":"Kawai","year":"2000","journal-title":"Nat Med"},{"key":"10.1016\/j.beem.2022.101661_bib98","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/ajt.15661","article-title":"First-in-human clinical trial to assess pharmacokinetics, pharmacodynamics, safety, and tolerability of iscalimab, an anti-CD40 monoclonal antibody","volume":"20","author":"Espie","year":"2020","journal-title":"Am J Transplant"},{"key":"10.1016\/j.beem.2022.101661_bib99","first-page":"105","article-title":"A\u00a0novel anti-CD40 monoclonal antibody, iscalimab, for control of graves hyperthyroidism-A proof-of-concept trial","author":"Kahaly","year":"2020","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2022.101661_bib100","doi-asserted-by":"crossref","first-page":"691781","DOI":"10.3389\/fendo.2021.691781","article-title":"Precision medicine in graves' disease: CD40 gene variants predict clinical response to an anti-CD40 monoclonal antibody","volume":"12","author":"Faustino","year":"2021","journal-title":"Front Endocrinol"}],"container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X22000483?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X22000483?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T16:59:29Z","timestamp":1761497969000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521690X22000483"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":100,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S1521690X22000483"],"URL":"https:\/\/doi.org\/10.1016\/j.beem.2022.101661","relation":{},"ISSN":["1521-690X"],"issn-type":[{"value":"1521-690X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genetics and epigenetics of autoimmune thyroid diseases: Translational implications","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beem.2022.101661","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101661"}}